KVUE
Get informed when a big investor buys or sells
+ FollowAugust 7, 2025 - AI Summary
Undervalued by 154.1% based on the discounted cash flow analysis.
| Market cap | $34.79 Billion |
|---|---|
| Enterprise Value | $42.47 Billion |
| Dividend Yield | $0.83 (4.58%) |
| Earnings per Share | $0.77 |
| Beta | 0.5 |
| Outstanding Shares | 1,918,000,000 |
| P/E Ratio | 21.43 |
|---|---|
| PEG | 45.39 |
| Price to Sales | 2.63 |
| Price to Book Ratio | 3.68 |
| Enterprise Value to Revenue | 2.78 |
| Enterprise Value to EBIT | 14.75 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.83 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3711▼ 23.61% |
|---|---|
| Total Calls | 18,257,600▼ 60.35% |
| Total Puts | 6,775,200▼ 75.77% |
Holdings and activity of institutional investors.
| Ownership % | 90.54%▼ 4.02% |
|---|---|
| Total Invested | $29.91B▼ 4.38% |
| Investors Holding | 1,045▼ 61.00% |
No data
Provides critical analysis and 'revenue estimates' for tax legislation, directly influencing corporate tax structures and the overall tax burden on Kenvue.
Controls taxation and trade policy, which directly impact Kenvue's corporate profitability, supply chain costs, and international market access.
Directly regulates the FDA, a primary oversight body for Kenvue's over-the-counter drugs, cosmetics, and other consumer health products, and influences labor laws affecting its workforce.
Oversees antitrust laws, crucial for large corporations regarding mergers, acquisitions, and market dominance, and intellectual property protection, vital for Kenvue's brands and product formulations.
Has vast jurisdiction over interstate commerce and oversees the FTC, which directly regulates advertising, marketing, and competition for consumer health products like Kenvue's.